Rapamycin-Resistant Polyclonal Th1/Tc1 Cell Therapy (RAPA-201) Safely Induces Disease Remissions in Relapsed, Refractory, Multiple Myeloma

0
243
This clinical trial evaluated RAPA-201 therapy in combination with fludarabine-sparing low-dose host conditioning for the treatment of patients with relapsed, refractory multiple myeloma.
[Journal for Immunotherapy of Cancer]
Full Article